We are live on ! Find out more
SCM

Soleus Capital Management Portfolio holdings

AUM $2.47B
1-Year Est. Return 115.63%
This Fund
S&P 500
This Quarter Est. Return
+25.2%
1 Year Est. Return
+115.63%
3 Year Est. Return
+435.52%
5 Year Est. Return
+604.31%
10 Year Est. Return
–
AUM
$697M
AUM Growth
-$38.9M
Cap. Flow
-$135M
Cap. Flow %
-19.43%
Top 10 Hldgs %
45.64%
Holding
96
New
21
Increased
21
Reduced
26
Closed
24

Top Buys

Rank Stock Value
1
VCEL icon
Vericel Corp
VCEL
+$12.7M
2
NARI
Inari Medical, Inc. Common Stock
NARI
+$8.91M
3
CCCC icon
C4 Therapeutics
CCCC
+$8.29M
4
CELC icon
Celcuity
CELC
+$7.84M
5
HCA icon
HCA Healthcare
HCA
+$7.74M

Top Sells

Rank Stock Value
1
ILMN icon
Illumina
ILMN
+$27.1M
2
UTHR icon
United Therapeutics
UTHR
+$26.9M
3
CVS icon
CVS Health
CVS
+$18.4M
4
NVST icon
Envista
NVST
+$15.7M
5
LLY icon
Eli Lilly
LLY
+$14.8M

Sector Composition

Rank Sector Weight
1 Healthcare 97.09%
2 Consumer Staples 1.8%
3 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CVS icon
26
CVS Health
CVS
$125B
$8.83M 1.27%
94,754
-191,146
-67% -$18.4M
HCA icon
27
HCA Healthcare
HCA
$88.8B
$8.29M 1.19%
+34,550
New +$7.74M
THER
28
DELISTED
THERATECHNOLOGIES INC COM
THER
$7.77M 1.11%
8,799,125
+791,411
+10% +$699K
BCYC
29
Bicycle Therapeutics
BCYC
$277M
$7.65M 1.1%
+258,400
New +$6.93M
AXGN icon
30
Axogen
AXGN
$2.4B
$7.54M 1.08%
755,998
+331,000
+78% +$3.68M
RNAM
31
DELISTED
Avidity Biosciences
RNAM
$6.88M 0.99%
+310,000
New +$4.62M
ENTA icon
32
Enanta Pharmaceuticals
ENTA
$391M
$6.41M 0.92%
137,814
+14,800
+12% +$675K
JBIO
33
Jade Biosciences
JBIO
$1.3B
$6.36M 0.91%
+6,203
New +$4.5M
OFIX icon
34
Orthofix Medical
OFIX
$432M
$6.06M 0.87%
+295,300
New +$5.21M
FDMT icon
35
4D Molecular Therapeutics
FDMT
$544M
$5.66M 0.81%
+254,700
New +$3.93M
SNDX icon
36
Syndax Pharmaceuticals
SNDX
$1.72B
$5.6M 0.8%
+220,000
New +$5.13M
DICE
37
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
$5.41M 0.78%
173,447
-361,911
-68% -$11.8M
STAA icon
38
STAAR Surgical
STAA
$1.16B
$5.35M 0.77%
+110,200
New +$6.91M
ENOV icon
39
Enovis
ENOV
$1.75B
$5.08M 0.73%
95,000
-7,100
-7% -$366K
ILMN icon
40
Illumina
ILMN
$30.4B
$4.91M 0.7%
24,941
-130,904
-84% -$27.1M
ETNB
41
DELISTED
89bio
ETNB
$4.82M 0.69%
379,000
+49,000
+15% +$441K
DXCM icon
42
DexCom
DXCM
$31.3B
$4.53M 0.65%
40,000
+16,164
+68% +$1.77M
IMGO
43
DELISTED
Imago BioSciences, Inc. Common stock
IMGO
$4.13M 0.59%
115,000
-98,000
-46% -$2.45M
AXSM icon
44
Axsome Therapeutics
AXSM
$10.8B
$3.86M 0.55%
+50,000
New +$2.99M
CELL
45
DELISTED
PhenomeX Inc. Common Stock
CELL
$3.56M 0.51%
+1,330,000
New +$3.51M
NPCE icon
46
Neuropace
NPCE
$464M
$3.53M 0.51%
2,369,003
+35,000
+1% +$77.8K
PHVS icon
47
Pharvaris
PHVS
$2.31B
$3.49M 0.5%
+310,000
New +$1.63M
RXDX
48
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
$3.42M 0.49%
+31,100
New +$2.02M
TGTX icon
49
TG Therapeutics
TGTX
$7.49B
$2.82M 0.4%
+238,000
New +$1.73M
TMDX icon
50
Transmedics
TMDX
$2.53B
$2.68M 0.39%
43,500
-131,800
-75% -$7.01M
1
2
3 4

Similar funds

TW
Trajan Wealth Scottsdale, Arizona $2.48B AUM 17.44% 1-Year Est. Return
M
Mirova Paris, France $2.46B AUM 11.42% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $2.48B AUM 72.25% 1-Year Est. Return
BL
Balentine LLC Atlanta, Georgia $2.48B AUM 17.44% 1-Year Est. Return
FFA
First Foundation Advisors Irvine, California $2.48B AUM 18.56% 1-Year Est. Return
GWM
Greenwich Wealth Management Greenwich, Connecticut $2.45B AUM 39.53% 1-Year Est. Return
Q
QVR San Francisco, California $2.49B AUM 48.58% 1-Year Est. Return
SIM
Stratos Investment Management Beachwood, Ohio $2.49B AUM 17.24% 1-Year Est. Return

Soleus Capital Management's Q4 2022 Portfolio in Review

As of Q4 2022, Soleus Capital Management held 96 positions worth $697M, down 5.3% from $736M the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Soleus Capital Management withdrew a net $135M in Q4 2022, closing 24 positions and reducing 26 holdings. Its most notable exit was Envista, an estimated $15.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 93% a quarter earlier, followed by Consumer Staples and Financials.

Against the trend, Soleus Capital Management opened a new position in HCA Healthcare worth $8.29M.

  • Soleus Capital Management's largest Q4 2022 buy was HCA Healthcare: 34,550 shares worth $8.29M.
  • Soleus Capital Management added most to Vericel Corp in Q4 2022, an estimated $12.7M increase.
  • Soleus Capital Management's biggest Q4 2022 reduction was Illumina, cutting an estimated $27.1M.
  • Soleus Capital Management fully exited Envista in Q4 2022, selling an estimated $15.7M.
  • Soleus Capital Management's ten largest holdings make up 46% of its $697M portfolio in Q4 2022.
  • Soleus Capital Management opened 21 new positions and closed 24 in Q4 2022.
  • Soleus Capital Management's portfolio value fell 5.3% quarter-over-quarter to $697M.

Based on Soleus Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.